An integrated approach to the treatment of infectious lesions of the upper respiratory tract in pediatric practice

Introduction. The article substantiates a comprehensive bioregulatory approach to the treatment and immunorehabilitation of infectious respiratory diseases of the upper respiratory tract in pediatric practice.

Aim. To study the efficacy and tolerability of a bioregulatory drug in the complex treatment of children with infectious lesions of the upper respiratory tract.

Materials and methods. A prospective single-center study was conducted, 63 children: the main group of 32 children, the bioregulatory drug Tonsilgon® N 14 days was included in the complex of generally accepted therapy; 31 – the control group, only a complex of generally accepted therapy providing an anti-inflammatory effect was carried out. The age of children was 3–5 (4.3 ± 0.37) and 6–12 (9.2 ± 1.48) years in equal numbers by gender. Verification of the pathogen was carried out upon admission: in the main group, group A β-hemolytic streptococcus was detected in 7 (21.87%) patients, in the control group – in 6 (19.35%) patients; In the main group, Ig to Chlamydophila pneumoniae and Mycoplasma pneumoniae were in 9 (28.12%) patients, in the control group – 8 (25.8%), systemic antimicrobial therapy was prescribed.

Results. In the main group, on the 3rd day of examination, the treatment was assessed as highly effective in 21 (65.62%), effective in 10 (31.25%), and moderately effective in 1 (3.12%). On average, the effectiveness score for the group was 2.61 ± 0.14 points. Discussion. The broad spectrum of action, due to the diverse composition of the phytoimmunomodulator, has a stimulating effect on the activation of phagocytosis of macrophages and granulocytes, accelerating the elimination of pathogens, which is consistent with our data and with literature data.

Conclusions. An integrated approach to the treatment of inflammatory diseases of the oral cavity in children with the inclusion of a bioregulatory drug has a beneficial effect on the course of the inflammatory process in the oropharynx and stimulates the body’s resistance.

1. Samsygina GA, Vyzhlova EN. Once again about the problems of “frequently ill children” notion. Pediatriya – Zhurnal im G.N. Speranskogo. 2016;95(4):209–215. (In Russ.) Available at: https://pediatriajournal.ru/files/upload/mags/353/2016_4_4693.pdf.

2. Shabaldina EV, Akhtyamov DR, Grivtsova SV, Shelkovnikov AV, Apalko SV, Shabaldin AV. Efficacy of herbal medicine in the treatment and immunorehabilitation of preschool children with recurrent acute nasopharyngitis. Clinical Practice in Pediatrics. 2020;15(5):57–66. (In Russ.) https://doi.org/10.20953/1817-7646-2020-5-57-66.

3. Shumatova TA, Katenkova EYu, Gergert AV, Smagina MA, Belousova VA. Clinical analysis of the use of drug Tonsilgon N in children for the treat-ment of acute respiratory infections, accompanied by a sore throat. Farmateka. 2016;(11):100–105. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/33451.

4. Drynov GI, Ivanyushina OK, D’yakova FN. Results of therapy for chronic tonsillitis in children using Tonsilgon. Children’s Doctor. 2011;(1):76–77. (In Russ.) Available at: https://medi.ru/info/10974.

5. Киселев ОИ, Маринец ИГ, Соминина АА. Грипп и другие респираторные инфекции: эпидемиология, профилактика, диагностика и терапия. СПб.; 2013. 244 с.

6. Abrosimova M, Sadykov M. Realization issues of patient’s autonomy principle in the outpatient pediatric practices. Current Pediatrics. 2007;6(4):7–10. (In Russ.) Available at: https://vsp.spr-journal.ru/jour/article/view/1243.

7. Kolobukhia LV. Viral infections of respiratory tract. RMJ. 2000;8(13):559. (In Russ.) Available at: https://www.rmj.ru/articles/infektsionnye_bolezni/Virusnye_infekcii_dyhatelynyh_putey/?utm_source=google.com&utm_medium=organic&utm_campaign=google.com&utm_referrer=google.com.

8. Lysenko IM, Barkun GK, Zhuravleva LN, Fedorischko NN. New approaches to rehabilitation of frequently ill children: control and correction of cardiovascular and metabolic disorders. Journal of the Grodno State Medical University. 2018;6(16):706–710. (In Russ.) https://doi.org/10.25298/22218785-2018-16-6-706-710.

9. Samsygina GA. On recurrent respiratory tract infections and dispensary group of sickly children. Children Infections. 2012;3(11):52–53. (In Russ.) Available at: https://cyberleninka.ru/article/n/o-retsidiviruyuscheyinfektsii-respiratornogo-trakta-i-dispansernoy-gruppe-chastoboleyuschih-detey.

10. Kharlamova FS, Shamsheva OV, Kladova OV, Andzhelʹ AE, Denisova AV. Immunomodulators of microbial origin in treatment and prevention of respiratory infections in children with long and frequent diseases. Lechaschi Vrach. 2016;(12):48–50. (In Russ.) Available at: https://www.lvrach.ru/2016/12/15436621.

11. Svistushkin VM, Volkova KB. Use of antiseptic herbal-based medicaments in case of upper respiratory tractus pathology. Therapy. 2018;(1):72–76. (In Russ.) Available at: https://therapy-journal.ru/ru/archive/article/35949.

12. West JV. Acute upper airway infections. Childhood respiratory infections. Br Med Bull. 2002;61(1):215–230. https://doi.org/10.1093/bmb/61.1.215.

13. Wong DO, Blumberg DA, Lowe LG. Guidelines for the use of antibiotics in acute upper respiratory tract infections. Am Fam Physician. 2006;74(6):956–966. Available at: https://pubmed.ncbi.nlm.nih.gov/17002029.

14. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Aloboid I, Baroody F et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinology. 2012;2012:1–229. https://doi.org/10.4193/Rhino12.000.

15. Pikuza OI, Fayzullina RA, Zakirova AM, Suleymanova ZYa, Rashitova EL, Volyanyuk EV. Bactericidal resources of oral neutrophils as a marker of the clinical course of inflammatory respiratory diseases in children. Kazan Medical Journal. 2020;101(5):740–748. (In Russ.) https://doi.org/10.17816/KMJ2020-740.

16. Pikuza OI, Zakirova AM, Moroz TB. Clinical effectiveness of a screening approach to differentiated prescription of antibacterial therapy for children with acute tonsillopharyngitis. Kazan Medical Journal. 2020;101(6):805–811. (In Russ.) https://doi.org/10.17816/KMJ2020-805.

17. Pikuza OI, Zakirova AM, Samorodnova EA, Fayzullina RA, Volyanyuk EV. Clinical significance of integral registration of markers of endotoxic immunity and colonization resistance of buccal epithelial cells in recurrent bronchitis in adolescents. Practical Medicine. 2024;22(2):96–103. (In Russ.) https://doi.org/10.32000/2072-1757-2024-2-96-103.

18. Santee CA, Nagalingam NA, Faruqi AA, DeMuri GP, Gern JE, Wald ER et al. Nasopharyngeal microbiota composition of children is related to the frequency of upper respiratory infection and acute sinusitis. Microbiome. 2016;4(1):34. https://doi.org/10.1186/s4016801601799.

19. Shabaldina EV, Shabaldin AV. Upper respiratory dysbiosis in children. Fundamental and Clinical Medicine. 2017;1(2):65–74. (In Russ.) Available at: https://fcm.kemsmu.ru/jour/article/view/31/29.

20. Shabaldin AV, Shabaldina EV, Simbirtsev AS. Features of the microbiome of the upper respiratory tract in children with recurrent respiratory diseases. Russian Journal of Infection and Immunity. 2017;7(4):341–349. (In Russ.) https://doi.org/10.15789/2220761920174341349.

21. Krasnova EI, Chretien SO, Vasyunin AV. Acute streptococcal infection of the oropharynx in pediatric practice – a problem and solutions. Lechaschi Vrach. 2011;(8). (In Russ.) Available at: https://www.lvrach.ru/2011/08/15435264.

22. Safronenko LA, Lukashevich MG, Butko IL. Compliance of paediatricians to the guidelines on the use of antimicrobials in respiratory infections. Klinicheskaia Mikrobiologiia i Antimikrobnaia Khimioterapiia. 2017;19(1):63–66. (In Russ.) Available at: http://old.antibiotic.ru/cmac/2017/n1.shtml#063.

23. Subbotina MV, Buksha IA, Platonenko OI. Tonsilgon N as an anti-inflammatory and immunomodulatory drug in acute ENT pathology. Pulmonology and Otolaryngology. 2012;(4):24–27. (In Russ.) Available at: https://umedp.ru/articles/tonzilgon_n_kak_protivovospalitelnyy_i_immunomoduliruyushchiy_preparat_pri_ostroy_lorpatologii.html.

24. Vavilova VP, Abramov-Sommariva D, Steindl G, Vonnemann M, Ryzhova EG, Rusova TV et al. Effectiveness and tolerability of Tonsilgon® N in the treatment of recurrent upper respiratory tract infections in children: a non-interventional study in Russia. RMJ. 2017;(5):350–358. (In Russ.) Available at: https://clinphytoscience.springeropen.com/articles/10.1186/s40816-016-0020-9.

25. Vladimirova TY, Fatenkov OV, Sokolova SY, Martynova AB. Management peculiarities of patients with chronic tonsillitis in comorbid conditions. Meditsinskiy Sovet. 2023;17(19):165–171. (In Russ.) https://doi.org/10.21518/ms2023-343.

26. Selkova EP, Oganesyan AS, Gudova NV, Ermilova NV. Comprehensive approach to the acute respiratory viral infections treatment. RMJ. Medical Review. 2019;(3):10–12. (In Russ.) Available at: https://viewer.rusneb.ru/ru/000199_000009_07000447228?page=12&rotate=0&theme=white.

27. Kovalenko LP, Shipaeva EV, Kolchenko II. Immunocorrective properties of the herbal medicine Tonsilgon N. Breast cancer. Immunologiya. 2008;16(25):1684–1687. (In Russ.) Available at: https://www.rmj.ru/articles/immunologiya/Immunokorrigiruyuschie_svoystvafitopreparata_Tonzilgon_N.

28. Dronov IA, Geppe NA, Kolosova NG, Velikoretskaya MD. A combination herbal medicine in the treatment of children with recurrent tonsillopharyngitis. Clinical Practice in Pediatrics. 2020;15(4):16–24. (In Russ.) https://doi.org/10.20953/1817-7646-2020-4-16-24.

29. Boyko NV, Kalinkina MI, Gorshkova GI. Conservative treatment of chronic tonsillitis. Detskaya Otorinolaringologiya. 2012;(3):22–24. (In Russ.) Available at: https://www.elibrary.ru/rcgtkp.

30. Drozdova MV, Ryazantsev SV. The experience of administration of the preparation tonsilgon n in treatment of chronic tonsillitis in sickly children. Rossiiskaya Otorinolaringologiya. 2016;(5):120–125. (In Russ.) https://doi.org/10.18692/1810-4800-2016-5-120-125.

31. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl. 29):1–464. https://doi.org/10.4193/Rhin20.600.

32. Калюжин ОВ. Острые респираторные вирусные инфекции: современные вызовы, противовирусный ответ, иммунопрофилактика и иммунотерапия. М.: Медицинское информационное агентство; 2014. 144 с. Режим доступа: https://piratebooks.ru/threads/ostrie-respiratornie-virusnieinfekcii-sovremennie-vizovi-protivovirusniyotvet-immunoprofilaktika-iimmunoterapiya.250209.

33. Wronski S, Dannenmaier J, Schild S, Macke O, Müller L, Burmeister Y et al. Engystol reduces onset of experimental respiratory syncytial virusinduced respiratory inflammation in mice by modulating macrophage phagocytic capacity. PLoS ONE. 2018;13(4):e0195822. https://doi.org/10.1371/journal.pone.0195822.

34. Drynov GI, Ivanyushina OK, Dyakova FN. Prevention and therapy of respiratory infections during a course of specific immunotherapy. Lechaschi Vrach. 2001;(3):45–47. (In Russ.) Available at: https://www.lvrach.ru/2001/03/4528623.

35. Drynov GI, Ivanyushina OK, Dyakova FN. Results of treatment of children with chronic tonsillitis with the drug Tonzilgon N. Children’s Doctor. 2001;(1):67–69. (In Russ.) Available at: https://medi.ru/info/10974.

36. Zaplatnikov AL, Girina AA, Lepiseva IV, Maykova ID, Svintsitskaya VI, Dubovets NF. On the issue of rational therapy of acute respiratory infections in children in conditions of growing antibiotic resistance. Pediatrics. Consilium Medicum. 2018;(4):37–41. (In Russ.) https://doi.org/10.26442/24138460.2018.4.180133.

37. Hostanska K, Melzer J, Amon A, Saller R. Suppression of interleukin (IL)-8 and human beta defensin-2 secretion in LPS-and/or IL-1ß-stimulated airway epithelial A549 cells by a herbal formulation against respiratory infections (BNO 1030). J Ethnopharmacol. 2011;134:228–233. https://doi.org/10.1016/j.jep.2010.12.006.

38. Berger T. Tolerability and efficacy of a herbal combination preparation in children and adolescents with recurrent infections of the upper respiratory tract. MMW-Fortschr Med. 2008;150:85–90. Available at: https://pubmed.ncbi.nlm.nih.gov/18712128.

39. Pahl A. Imupret modulates the innate and adaptive immune system parameters in vitro. Planta Med. 2009;75:PJ200. Available at: https://www.researchgate.net/publication/247474457_Imupret_modulates_the_innate_and_adaptive_immune_system_parameters_in_vitro.

40. Ковальчук ЛВ. Клиническая иммунология и аллергология с основами общей иммунологии. М.: ГЭОТАР-Медиа; 2012. 640 с. Режим доступа: https://www.studentlibrary.ru/book/ISBN9785970422410.html.

41. Shabaldina EV, Kutenkova NE, Shabaldin AV, Tihonjuk VP, Lisachenko GV. Singularities of immune status and of status of cytokines at children with hypertrophy of lymphoid pharyngeal ring and with an accompanying allergy to infectious antigens. Rossiiskaya Otorinolaringologiya. 2012;(2):118–123. (In Russ.) Available at: https://cyberleninka.ru/article/n/osobennosti-immunnogo-i-tsitokinovogo-statusov-u-detey-sgipertrofiey-limfoidnogo-glotochnogo-koltsa-i-soputstvuyuscheyallergiey-k/viewer.

42. Baranov AA, Lobzin YuV, Namazova-Baranova LS, Tatochenko VK, Uskov AN, Kulichenko TV et al. Acute Respiratory Viral Infection in Children: Modern Approaches to Diagnosis and Treatment. Pediatric Pharmacology. 2017;14(2):100–108. (In Russ.) https://doi.org/10.15690/pf.v14i2.1724.

43. Letifov GM, Boyko NV, Kim AS, Stagnieva IV. Evaluation of the effectiveness of treatment of acute tonsillopharyngitis in acute respiratory viral infections in children. Pediatriya – Zhurnal im G.N. Speranskogo. 2018;97(4):168–172. (In Russ.) Available at: https://pediatriajournal.ru/archive?show=365§ion=5294.

44. Gurov AV, Muzhichkova AV, Kelemetov AA. Topical issues in the treatment of chronic tonsillitis. Meditsinskiy Sovet. 2021;(6):67–73. (In Russ.) https://doi.org/10.21518/2079-701X-2021-6-67-73.

45. Letifov GM, Chebotareva YuYu, Kolodyazhnaya EG. Special aspects of reproductive system and hormonal status development in adolescents girls with chronic pyelonephritis. Nephrology. 2014;18(5):59–62. (In Russ.) Available at: https://journal.nephrolog.ru/jour/article/view/49.

46. Артюшкин СА, Еремина НВ, Рязанцев СВ, Карнеева ОВ, Крюков АИ, Кунельская НЛ и др. Хронический тонзиллит: клинические рекомендации. 2021. Режим доступа: https://legalacts.ru/doc/klinicheskierekomendatsii-khronicheskii-tonzillit-utv-minzdravom-rossii.

47. Геппе НА, Горелов АВ, Козлова ЛВ, Кондюрина ЕГ, Малахов АБ. Острые инфекции дыхательных путей у детей. Диагностика, лечение, профилактика: клиническое руководство. 2-е изд. М.: МедКом-Про; 2020. 232 с. Режим доступа: https://ph.medcompro.ru/wp-content/uploads/2021/05/OIDP-verstka-05.11-1-15-1.pdf.

48. Selimzyanova LR, Vishneva EA, Fedoseenko MV, Promyslova EA. Phytotherapy: Present State of the Issue. Pediatric Pharmacology. 2016;13(5):488–493. (In Russ.) https://doi.org/10.15690/pf.v13i5.1645.

49. Promyslova EA, Selimzyanova LR, Vishneva EA. Diagnosis and therapy of acute streptococcal tonsillopharyngitis: modern recommendations. Pediatric Pharmacology. 2013;10(6):10–14. (In Russ.) Available at: https://cyberleninka.ru/article/n/diagnostika-i-terapiya-ostrogostreptokokkovogo-tonzillofaringita-sovremennye-rekomendatsii/viewer.

50. Тюменев АВ, Шабалдина ЕВ, Шабалдин АВ, Симбирцев АС, Рязанцев СВ. Способ определения провоспалительных и проаллергических интерлейкинов в назальном секрете у детей раннего и дошкольного возраста для диагностики этиологии рецидивирующих острых ринофарингитов и аденоидитов. Патент RU 2013146333, 20.07.2015. Режим доступа: https://rusneb.ru/catalog/000224_000128_2013146333_20150427_A_RU.

51. Korenyuk ES. Disturbances of the respiratory tract microbiota in children with respiratory diseases (literature review). Child’s Health. 2018;13(5):506–514. (In Russ.) https://doi.org/10.22141/2224-0551.13.5.2018.141569.

52. Gurov AV, Yushkina MA. Opportunities of Tonsilgon® N use in complex treatment of chronic tonsillitis. Consilium Medicum. 2018;20(11):20–24. (In Russ.) https://doi.org/10.26442/20751753.2018.11.000027.

53. Пальчун ВТ (ред.). Воспалительные заболевания глотки. М.: ГЭОТАРМедиа; 2012. 288 с. Режим доступа: https://www.rosmedlib.ru/book/ISBN9785970421437.html.

54. Пальчун ВТ, Магомедов ММ, Лучихин ЛА. Оториноларингология. М.: ГЭОТАР-Медиа; 2016. 584 с. Режим доступа: https://www.geotar.ru/lots/NF0000687.html.

55. Blotsky AA, Antipenko VV. Role of tonsillectomy for patients withdecompensed form of chronic tonsillitis and diseases connected with it. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2020;26(2):58–68. (In Russ.) Available at: https://journals.eco-vector.com/2310-3825/issue/viewIssue/8865/pdf_9.

56. Piskunov VS, Nikitin NA. Experience of the usage of Tonsilgon® N in the complex treatment of chronic tonsillitis with irrigations of palatine tonsils in adults. Consilium Medicum. 2018;20(3):48–52. (In Russ.) Available at: https://consilium.orscience.ru/2075-1753/article/view/95011.

57. Stagnieva IV, Boyko NV, Kim AS, Bykova VV. The prevalence of peritonsillar abscesses in children. Russian Otorhinolaryngology. 2019;18(3):54–58. (In Russ.) https://doi.org/10.18692/1810-4800-2019-3-54-58.

58. Krouse JH, Altman KW. Rhinogenic laryngitis, cough and the unified airway. Otolaryngol Clin North Am. 2010;43(1):111–121. https://doi.org/10.1016/j.otc.2009.11.005.

59. Ivanov VA, Sharapov NV, Zaplatnikov AL. The health status of frequently ill children and increasing the effectiveness of their sanatorium rehabilitation. RMJ. 2007;(21):1559 (In Russ.) Available at: https://www.rmj.ru/articles/pediatriya/Sostoyanie_zdorovyya_chasto_boleyuschih_detey_i_povyshenie_effektivnosti_ih_sanatornogo_ozdorovleniya/.

60. Svistushkin VM, Nikiforova GN, Shevchik EA, Zolotova AN, Nikiforova AN, Sivokhin DA. Efficacy of herbal medicines in the treatment of acute respiratory infections in real clinical practice. Consilium Medicum. 2022;24(9):579–587. (In Russ.) https://doi.org/10.26442/20751753.2022.9.201944.

61. Firsova IV, Mikhalchenko VF, Popova AN, Krainov SV. The use of septolete and tonsilgon in the local treatment of inflammatory periodontal diseases. Lekarstvennyi Vestnik. 2016;10(4):6–11. (In Russ.) Available at: https://www.volgmed.ru/uploads/journals/articles/1484050760-drugsbulletin-2016-4-2815.pdf.

62. Khadyeva MN, Blashkova SL, Galiullin AN. Prevalence of periodontal diseases in children under 6 years old in the Republic of Tatarstan: impact of age and family structure. Pediatric Dentistry and Dental Prophylaxis. 2023;23(4): 361–370. (In Russ.) https://doi.org/10.33925/1683-3031-2023-659.

63. Firsova IV, Mikhalchenko VF, Mikhalchenko DV. Approach to the patient in the diagnosis of precancerous lesions of the mucous membranes of the mouth and vermilion border. Journal of Volgograd State Medical University. 2013;10(1):3–6. (In Russ.) Available at: https://journals.ecovector.com/1994-9480/article/view/118454.

64. Барера ГМ (ред.). Пародонтология. М.: МЕДпресс-информ; 2014. 548 с. Режим доступа: https://book-med.ru/products/18959822.

65. Еловикова ТМ. Арифметика пародонтологии: Ручные инструменты в пародонтологии. М.: МЕДпресс-информ; 2006. 80 с. Режим доступа: https://www.fb2portal.ru/stomatologiya/arifmetika-parodontologii.

66. Setdikova NKh, Latysheva TV. Immunomodulators in clinical practice. Doktor.Ru. 2010;(2):9–13. (In Russ.) Available at: https://cyberleninka.ru/article/n/primenenie-immunomodulyatorov-v-obscheklinicheskoypraktike/viewer.

67. Жулев ЕН, Круглова НВ, Кочубейник АВ. Лечение заболеваний пародонта. Н. Новогород: Изд-во НижГМА; 2016. 162 с. Режим доступа: https://e.lanbook.com/book/240449.

68. Ковалевский АМ. Лечение пародонтита: практическое руководство. М.: Медицинское информационное агентство; 2010. 160 с. Режим доступа: https://www.mmbook.ru/catalog/stomatologija/zabolewanijaparodonta/104776-detail.

69. Firsova IV, Mikhalchenko VF. Social and psychological aspects of patient compliance in dental practice. Journal of Volgograd State Medical University. 2007;4(2):3–9. (In Russ.) Available at:https://journals.eco-vector.com/1994-9480/article/view/139955.

70. Ушаков РВ, Царев ВН. Местное антимикробное лечение в стоматологии. М.: Медицинское информационное агентство; 2004. 136 с. Режим доступа: https://www.mmbook.ru/catalog/stomatologija/poleznokazhdomu-stomatologu/100838-detail.

71. Tsepov LM, Nikolaev AI, Nesterova MM, Tsepova EL. Pathogenetic features of chronic periodontal pathology development (review). Vestnik of Smolensk State Medical Academy. 2018;17(3):206–214. (In Russ.) Available at: https://elibrary.ru/ybjnqd.

72. Kotas ME, Medzhitov R. Homeostasis, Inflammation and disease susceptibility. Cell. 2015;160(5):816–827. https://doi.org/10.1016/j.cell.2015.02.010.

73. Nathan C. Points of control in inflammation. Nature. 2002;420(6917):846–852. https://doi.org/10.1038/nature0132075.

74. Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140(6):871–882. https://doi.org/10.1016/j.cell.2010.02.029.

75. McDade TW. Early environments and the ecology of inflammation. Proc Natl Acad Sci USA. 2012;109(Suppl.):17281–17288. https://doi.org/10.1073/pnas.1202244109.

76. Itoh M, Suganami T, Hachiya R, Ogawa Y. Adipose tissue remodeling as homeostatic inflammation. Int J Inflam. 2011;2011:720926. https://doi.org/10.4061/2011/720926.

77. Mann CJ, Perdiguero E, Kharraz Y, Aguilar S, Pessina P, Serrano A, Muñoz-Cánoves P et al. Aberrant repair and fibrosis development in skeletal muscle. Skelet Muscle. 2011;1(1):21. Available at: https://skeletalmusclejournal.biomedcentral.com/articles/10.1186/2044-5040-1-21.

78. Serrano AL, Mann CJ, Vidal B, Ardite E, Perdiguero E, MunozCanoves P. Cellular and molecular mechanisms regulating fibrosis in skeletal muscle repair and disease. Curr Top Dev Biol. 2011;96:167–201. https://doi.org/10.1016/B978-0-12-385940-2.00007-3.

79. Holt AP, Salmon M, Buckley CD, Adams DH. Immune interactions in hepatic fibrosis. Clin Liver Dis. 2008;12(4):861–882. https://doi.org/10.1016/j.cld.2008.07.002.

80. Smith A. Bioregulatory medicine: practical aspects. Pharmacy. 2017;66(1):42–47. (In Russ.) Available at: https://pharmaciyajournal.ru/ru/25419218-2017-01-10.

81. Reviakina VA, Astaf’eva NG, Geppe NA, Kaliuzhin OV. Updated PRIMA consensus document to assist the practicing physician. Pediatrics. Consilium Medicum. 2021;(2):109–112. (In Russ.) https://doi.org/10.26442/26586630.2021.2.200992.

82. Hoefakker S, van Erve E, Deen C. Immuno-histochemical defection of cotocalising cytocine and antibodyproducing cells in the extrafollicular ared of human palatine tonsils. Clin Exp Immunol. 1993;93(2):223–228. https://doi.org/10.1111/j.1365-2249.1993.tb07970.x.

83. Пальчун ВТ (ред.). Руководство по очаговой инфекции в оториноларингологии. М.: ГЭОТАР-Медиа; 2015. 224 с. Режим доступа: https://www.rosmedlib.ru/book/ISBN9785970434741.html.

84. Sutovskai DV, Burlutskaia AV. Combination of physiological factors and herbal therapy in rehabilitation treatment of often painful children. Kuban Scientific Medical Bulletin. 2017;(4):128–134. (In Russ.) https://doi.org/10.25207/1608-6228-2017-24-4-128-134.

85. Fazylov VKh, Sitnikov IG, Silina EV, Shevchenko SB, Mozhina LN, Zamyatina LL et al. Treatment for acute respiratory viral infection and influenza in daily clinical practice: Results of the multicenter international observational FLU-EE study. Terapevticheskii Arkhiv. 2016;88(11):68–75. (In Russ.) https://doi.org/10.17116/terarkh2016881168-75.

86. Arztebl D. Phytopharmaka: Besonders für Kinder geeignet. Deutsches Ärzteblatt. 2002;99(23):A-1614/B-1260/C-1121. Available at: https://www.aerzteblatt.de/archiv/31909/Phytopharmaka-Besondersfuer-Kinder-geeignet.

87. Garashchenko TI, Selkova EP, Karneeva OV, Garashchenko MV, Oganesyan AS. Bioregulatory therapy in the treatment and prevention of upper respiratory tract diseases in children. Meditsinskiy Sovet. 2020;(18):32–41. (In Russ.) https://doi.org/10.21518/2079-701X-2020-18-32-41.

88. Ahn AC, Tewari M, Poon C-S, Phillips RS. The clinical applications of a systems approach. PLoS Med. 2006;3(7):e209. https://doi.org/10.1371/journal.pmed.0030209.

89. Chovatiya R, Medzhitov R. Stress, inflammation, and defense of homeostasis. Mol Cell. 2014;54(2):281–288. https://doi.org/10.1016/j.molcel.2014.03.030.

90. Mc Chesney JD, Venkataraman SK, Henri JT. Plant natural products: Back to the future or into extinction? Phytochemistry. 2007;68(14):2015–2022. https://doi.org/10.1016/j.phytochem.2007.04.032.

91. Belov VA, Karpova EP. Recoverability of the adaptive potential of the tonsils in chronic tonsillitis. A Review. Pediatrics. Consilium Medicum. 2024;(1):43–48. (In Russ.) https://doi.org/10.26442/26586630.2024.1.202796.

92. Кryukov AI, Kunelskaya NL, Tsarapkin GY, Izotova GN, Tovmasyan AS, Luchsheva YV. The study of the efficacy and safety of Tonsilgon® N in the treatment of chronic pharyngitis. Meditsinskiy Sovet. 2016;17:42–44. (In Russ.) https://doi.org/10.21518/2079-701X-2016-17-42-44.

93. Mal’tseva GS, Drozdova MV, Riazantsev SV, Zakharova GP, Bezshapochnyĭ SB. Tactics of conservative treatment of chronic adenoiditis in children. Vestnik Oto-Rino-Laringologii. 2019;84(2):36–39. (In Russ.) https://doi.org/10.17116/otorino20198402136.

94. Chethana R, Devan PP, Sushmitha K. The Role of Oxidants and Antioxidants in Chronic Tonsillitis. Indian J Otolaryngol Head Neck Surg. 2022;74(Suppl. 3): 5269–5274. https://doi.org/10.1007/s12070-020-02087-2.

95. Klimova II, Bazhenov DV. The effectiveness of a herbal preparation Tonsilgon N for the treatment of the children presenting with chronic adenoiditis. Vestnik Oto-Rino-Laringologii. 2014;(2):75–78. (In Russ.) Available at: https://www.mediasphera.ru/issues/vestnik-otorinolaringolo gii/2014/2/030042-46682014217.

96. Шульдяков АА, Ляпина ЕП (ред.). Дифференциальная диагностика заболеваний, протекающих с синдромом тонзиллита. Саратов; 2018. 108 с. Режим доступа: http://old.sgmu.ru/edu/learn/ordin/covid19/files/6.pdf.

97. Soldatsky YuL. Larynx diseases. Pediatric Pharmacology. 2008;5(2):20–25. (In Russ.) Available at: https://www.pedpharma.ru/jour/article/view/871.

98. Vavilova VP, Vavilova TA, Cherkayeva AK. Recurrent Acute Respiratory Infections in Children: Effectiveness and Safety of Phytotherapy. Pediatric Pharmacology. 2015;12(5):605–608. (In Russ.) https://doi.org/10.15690/pf.v12i5.1463.

99. Ammendola А. Effectiveness and tolerability of Tonsilgon N in the treatment of recurrent upper respiratory tract infections in children. Bonn, Germany; 2015. 21 р. Available at: https://doclinika.ru/wp-content/uploads/2015/10/Abr.pdf.

100. Vasyaeva AA, Arefieva NA. Immunotherapy for chronic pharyngitis: indications, results. RMJ. 2010;30(18):1864–1869. (In Russ.) Available at: https://www.rmj.ru/articles/otorinolaringologiya/Immunoterapiya_pri_hronicheskih_faringitah_pokazaniya_rezulytaty/.

101. Garashchenko MV. Herbal medicines in the prevention of acute respiratory diseases in children. Effective Pharmacotherapy. Pediatrics. 2011;(5):52–54. (In Russ.) Available at: https://umedp.ru/articles/fitopreparaty_v_profilaktike_ostrykh_respiratornykh_zabolevaniy_u_detey.html.

102. Kholodova IN, Syrieva TN, Kholodov DI. An integrated approach to the prevention and treatment of ARI. Meditsinskiy Sovet. 2019;(2):61–67. (In Russ.) https://doi.org/10.21518/2079-701X-2019-2-61-67.

103. Naber KG, Apolikhin O, Kozlov V, Kennedy D. Review of the Phytoneering Research & Experience Summit (PRES) 2019 “building bridges between nature’s healing potential and evidence-based medicine – 20 years of phytoneering”. Clin Phytosci. 2020;6. https://doi.org/10.1186/s40816020-0155-6.